Jill Schiaparelli joins AxoGen as senior VP
This article was originally published in Scrip
Regenerative medicine company AxoGen, which focuses on the commercialisation of proprietary products and technologies for peripheral nerve reconstruction and regeneration, has recruited Jill Schiaparelli as senior vice-president of business strategy and marketing. Ms Schiaparelli was formerly a principal of JS Strategic Partners, a consultancy which she founded. She also served as global vice-president of commercial strategy & business development for ApaTech before its acquisition by Baxter.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.